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Abstract 
Defining the autoantigenic targets of T cells involved in insulin- 
dependent diabetes mellitus (IDDM) is essential for understanding the 
pathogenesis of diabetes. IDDM results from the autoimmune destruction of 
the pancreatic islet (3 cells. The non-obese-diabetic (NOD) mouse is a murine 
model for spontaneous IDDM. T cells play an important role in the 
pathogenesis of diabetes, and CD8 T lymphocytes may be critical initiators of 
diabetes. Several [3-cell specific autoantigens of CD4 T cells have been 
identified. However, the autoantigens of CD8 T cells, which are likely to play 
an important role in the induction of diabetes, have not yet been identified. 
In this thesis we describe the application of a single-cell T cell assay, which 
takes advantage of a lacZ reporter construct, as a means to identify the target 
antigen of a diabetogenic CD8 T cell clone isolated from young NOD mice. 
Indicator cells are lacZ -inducible T-cell hybrids specific for the unknown 
antigen, and are shown here to turn blue in the presence of NOD mouse islets 
and the chromogenic substrate X-gal. These T cell hybrids, and COS-7 cells 
transfected with the murine MHC class I molecule as antigen-presenting 
cells, have been used to screen a NOD mouse islet cDNA library for the target 
antigen of the diabetogenic CD8 T cell clone. Our findings suggest that 
increasing the sensitivity and specificity of the lacZ assay may be necessary for 
detecting autoantigenic cDNA when it exists at very low frequencies in the 
cDNA library. 
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Introduction 
Overview 
Identifying the antigens on (3 cells targeted in type 1 diabetes is key to 
understanding the pathogenesis of this autoimmune disease, and promises to 
be useful for early diagnosis, and specific modulation of the immune process. 
Many researchers have searched for the antigen responsible for inducing 
diabetes in non-obese diabetic (NOD) mice. Their results have been enticing, 
yet remain controversial, and the existence of a dominant disease-initiating 
antigen has not been identified. Most of the candidate antigens proposed thus 
far are recognized by CD4 T cells, and not CD8 T cells, which may be the 
critical initiators of diabetes. Here we present the application of a recently 
introduced method that sensitively measures T-cell activation, and a strategy 
for identifying class I-restricted T cell antigens (Karttunen et al., 1992), as a 
means to elucidate the target antigen of cloned CD8 T cells (Wong et al., 1996) 
which were obtained at an early stage of disease in the NOD mouse, and 
which cause rapid-onset diabetes in the absence of CD4 T cells. 
1. T cell maturation: MHC restriction and self tolerance 
A critical function of T cells is to distinguish healthy tissue from 
infected tissue. They do so by recognizing foreign or altered proteins on the 
surface of cells in the context of MHC molecules. There are two classes of 
MHC molecules which differ in the source of the peptides they bind and carry 
to the cell surface. MHC class I molecules bind fragments of endogenous 
peptides, such as self antigens and fragments of viral proteins, generated in 
the cytosol and then transported to the endoplasmic reticulum (Figure 1) 
(Germain and Margulies, 1993). Extracellular antigenic proteins such as from 
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most bacteria are made visible to the immune system via the MHC class II 
presentation pathway. Class II molecules sample the contents of intracellular 
vesicles, and thus display peptide fragments which have been internalized by 
phagocytic cells which include macrophages, B cells, and specialized antigen 
processing cells (APCs) called dendritic cells (Figure 1) (Germain and 
Margulies, 1993). 
T cell precursors arise in the bone marrow and travel to the thymus 
(Ikuta et al., 1992). Here, gene rearrangements results in the assembly and 
expression of unique, exclusively membrane-bound T cell receptors (TCRs) 
(Matis, 1990). Subsequently, T cell maturation occurs and comprises two 
selective processes known as positive selection and negative selection. 
Positive selection ensures that T cells recognize self MHC molecules. 
All T cell receptors recognize MHC genes of the species, and virtually all of 
them recognize antigen in the form of peptide:MHC complexes. The ability of 
T cells to recognize specific antigens only in the context of self MHC 
molecules is also called MHC restriction. In order to receive important 
developmental signals from the thymic microenvironment, T cells must still 
possess an affinity for self-MHC molecules. Furthermore, MHC restriction 
ensures that T cells can potentially bind these molecules when they contain 
foreign antigenic peptides (Hogquist et al., 1994). Through a process that is 
not well understood T cells that recognize peptides in the context of MHC 
class I molecules (class-I-restricted) mature into cytotoxic T cells, expressing 
the CD8 co-receptor, whereas thymocytes that recognized peptides in the 
context of MHC class II molecules (class-II-restricted) generally mature into 
helper CD4 T cells (Kaye et al., 1989; Kisielow et al., 1988; Sha et al., 1988). CD4 
T cells differentiate into two functional types depending on their cytokine 
profiles: Thl cells and Th2 cells. Cells that do not encounter their restricting 
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Exogenous 
Figure 1. Schematic representation of the MHC class I and class II antigen 
processing pathways. Endogenous synthesis of protein antigens results in the 
production of peptide-MHC class I complexes. Peptide- MHC class 13 
complexes are generated only in cells that express MHC class II molecules, 
such as professional APCs, via endocytosed native proteins or phagocytosed 
bacteria. [Figure adapted from Kuby, J. (1997) Immunology 3rd ed (W.H. 
Freeman and Company. New York, New York) p. 257] 
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MHC molecule in the thymus die before attaining functional maturity (Surh 
and Sprent, 1994). 
Negative selection ensures that T cells are not reactive to MHC-peptide 
ligands found on self tissue, and are thus self-tolerant (von Boehmer et al., 
1993). Many thymocytes that are positively selected in the thymus possess 
receptors which are reactive to self peptides (Pullen et al., 1988; Sha et al., 
1988). These self-reactive thymocytes are eliminated either through 
programmed cell death in the thymus, also called clonal deletion, or remain 
functionally inactive in the periphery (Miller and Morahan, 1992). 
Only the thymocytes whose TCRs have met the two selection criteria: 
self-tolerance and self-restriction, develop into mature thymocytes (Sha et al., 
1988). This functions as a stringent screen mechanism upon developing 
thymocytes. In fact it is estimated that during negative and positive selection 
the vast majority of thymocytes, estimated around 98%, never leave the 
thymus but undergo apoptosis (Strasser, 1995; Surh and Sprent, 1994). 
2. Co-stimulatory molecules and peripheral T cell tolerance 
T cell activation is a complex process that requires at least two 
simultaneous signals from the same professional APC. The first is delivered 
through the T cell receptor (TCR), and involves recognition of a peptide 
fragment of antigen presented in the context of MHC molecules on the 
surface of an APC. The second signal, referred to as co-stimulation, is 
mediated through the binding of CD28 on T cells to co-stimulatory molecules 
on the same APC. Costimulation is required for optimal activation of naive 
T cells (Liu and Janeway, 1992). In fact, rather than activation, engagement of 
the TCR complex of naive T cells in the absence of co-stimulation leads to T 
cell anergy (Gimmi et al., 1993; Schwartz, 1990) or cell death (Liu and Janeway, 
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1992). It is thought that the requirement of two signals by one cell represents 
a mechanism for maintaining self-tolerance. Self tolerance would be lost if T 
cells recognizing self-antigens on the surface of tissue cells could be co¬ 
stimulated by resident or distant APCs, and not by the cell bearing the specific 
antigen (Schwartz, 1989). 
The best characterized costimulatory molecule, B7-1, interacts with 
receptors on the surface of T cells. These include CD28 and CTLA-4, a receptor 
which is expressed only once T cells are activated and for which B7-1 has a 
very high affinity to (Freeman et al., 1991; Linsley et al., 1991). B7-CD28 
interaction has been clearly shown to activate CD4 T cells, and leads to the 
production of cytokines such as IL-2 and IFN-y (Freeman et al., 1991; Gimmi et 
al., 1993; Linsley et al., 1991). The role of the costimulatory pathway for CD8 T 
cells is less clear, although it has been demonstrated that these cells can also 
be activated following B7-1 interaction (Tan et al., 1992). However, it seems 
that B7-1 interaction may stimulate T cell activation and not effector function 
(Harding and Allison, 1993). 
3. Autoimmunity: loss of self-tolerance 
Autoimmune disease occurs when a specific adaptive immune 
response is mounted against self antigens, or when self-tolerance is lost. 
Since negative selection, and peripheral inactivation by the absence of co¬ 
stimulation, are both very efficient processes it is unlikely that autoimmunity 
results from the failure of these two major mechanism of self tolerance 
(Janeway and Travers, 1997). Antigens that are expressed abundantly in the 
periphery induce clonal deletion or anergy. On the other hand, very rare 
antigens that are presented poorly on tissue cells are unable to activate 
antigen-specific T cells, which are present in the individual. These cells are 
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not normally activated, and are said to be immunologically ignorant. They 
require special circumstances to be activated and are likely responsible for 
most autoimmunity. Antigens which are presented at intermediate levels on 
tissue cells, such as those selectively expressed in the thyroid or the pancreatic 
islets, usually do not activate immunologically ignorant T cells, since the 
antigen would not be presented along with a co-stimulatory molecule. 
However, if the T cell was inappropriately activated, it would then go on to 
attack such tissues (Janeway and Travers, 1997; Katz et al., 1993). 
Another theory of the mechanisms underlying the loss of self¬ 
tolerance involves a change in the balanced state between aggressive and 
protective immune mechanisms. In both the human disease and the NOD 
mouse model, diabetes is preceded by a long phase of islet-cell-specific 
autoreactivity, before hyperglycemia is manifested, and this silent phase is 
thought to correspond to the active suppression of autoreactive T cells by 
regulatory, or suppressor T cells, in the periphery. In NOD mice, transfer of 
certain islet-specific T cell clones can prevent the destruction of pancreatic 
islet cells (Reich et ah, 1989). Likewise, during the early phase of insulitis 
mice are resistant to the transfer of disease by diabetogenic T cells (Bendelac et 
al., 1987), and this resistance can be broken down by selectively depleting CD4 
T cells (Sempe et al., 1994). It is unclear what triggers the breakdown from 
active tolerance to overt diabetes. However, it is thought that self-tolerance to 
pancreatic |3 cells is maintained by CD4 regulatory Th2 T cells, that produce IL- 
4 and IL-10, and provide help for the activation of B cell-mediated humoral 
responses. Th2 regulatory cells seem to suppress the activation of CD4 
autoreative Thl cells, that produce INF-y, and IL-2, and tend to activate 
macrophages and cytotoxic CD8 T cells (Cameron et al., 1998; Pilstrom et al., 
1995; Rabinovitch et al., 1995). There is evidence that when diabetes occurs 
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there is a shift to a Thl profile (Shimada et al., 1996), and that protection can 
be brought out from a shift from a Thl to a Th2 type of response (Cameron et 
al., 1997; Mueller et al., 1996). However, it is likely that a number of immune 
defects in addition to a Thl/Th2 imbalance contribute to the development of 
diabetes in the NOD mouse. Furthermore, the relevance of such deficiencies 
in NOD mice has yet to be correlated to human disease. 
4 The NOD mouse 
Overview 
Type 1 diabetes results from the interplay of genetic, environmental, 
and autoimmune factors, and leads to the selective destruction of insulin- 
producing pancreatic (3 cells. NOD mouse diabetes develops spontaneously, 
and possesses striking similarities to human type 1 diabetes. As such, the 
NOD mouse has become the most widely studied model of human diabetes. 
NOD mouse diabetes is not completely identical to human diabetes. For 
instance, there is no gender predominance in human diabetes whereas in 
NOD mice there is. In addition, high levels of islet-reactive autoantibodies 
exist in humans, whereas only low levels are found in NOD mice. 
Nevertheless, the NOD mouse model may serve to uncover the pathogenesis 
of diabetes, and allows for insight into the development of autoimmune 
diabetes in humans. 
The NOD mouse was described as a diabetes model in Japan in the late 
1970s (Makino et al., 1980). The mice develop an inflammatory infiltrate, 
called "insulitis", within the pancreatic islets at about 3-4 weeks of age, or the 
time of weaning. Dendritic cells and macrophages perhaps infiltrate first 
(Jansen et al., 1994), followed by T cells (both CD4 and CD8) and B cells (Kay et 
al., 1991; O'Reilly et al., 1994). Diabetes begins to occur at about 12 weeks of 
' 
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age, correlating with islet (3 cell destruction, and hyperglycemia (Bach, 1994). 
In addition, the appearance of autoantibodies (Bottazzo et al., 1989; Castano 
and Eisenbarth, 1990), defects in T cell activity (Serreze and Leiter, 1994), the 
sensitivity of the disease to immunosuppression (Bottazzo et al., 1989), and 
the presence of predisposing major histocompatibitiy complex (MHC) genes 
(Wicker et al., 1995) all suggest an autoimmune basis for the disease. 
A. Idd genes and MHC class II molecules 
IDDM in the NOD mouse is controlled by multiple susceptibility (Idd) 
genes both within and outside the MHC (Serreze and Leiter, 1994). As many 
as 15 loci critical to the IDDM process have been detected by genetic studies 
(Todd et al., 1991), though only a very few have been identified. 
The most important genetic component leading to IDDM susceptibility 
in NOD mice is the strain's MHC genes (Vyse and Todd, 1996). The MHC 
class II region, formerly Iddl, has been identified as a necessary but not 
sufficient predisposing genetic factor for diabetes (Tisch and McDevitt, 1996). 
The NOD mouse MHC class II molecule, I-A87, the homologue to human 
leukocyte antigen (HLA) DQ molecules, is composed of an I-Aad chain plus a 
unique I-A(3g7 chain that contains histidine-serine residues at amino acid 
positions 56 and 57, rather than the usual proline-aspartic acid residues seen 
in most other strains (Acha-Orbea and McDevitt, 1987). Diabetes can be 
prevented when I-Ag7 is altered by substitution at position 56 (Lund et al., 
1990). The I-Ag7 motif is remarkably similar to HLA DQ8, in that linkage 
between the lack of aspartic acid at the 57 position of the (3 chain and 
susceptibility to diabetes is also found with human DQ molecules (Kwok et 
al., 1996; Todd et al., 1988). 
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The nature of the binding properties of the I-Ag7 allele has been 
studied, but remains controversial. Work by Cohen and colleagues suggests 
that the peptide-binding motif of TA8? is similar to that of HLA DQ (Reizis et 
al., 1997; Reizis et al., 1997). Their findings suggest that the I-A8? molecule 
binds peptide adequately, and that it induces good T cell responses. Harrison 
et al (Harrison et al., 1997) propose a different I-A8? peptide-binding motif, 
though they also find that the I-A8? molecule is a good peptide-binder. On the 
other hand, others have found that I-Ag7 molecules are unstable, and are poor 
peptide binders (Carrasco-Marin et al., 1997). This has led to the hypothesis 
that, since elimination of autoreactive T cells requires a threshold period of 
time in contact with peptide-MHC complexes (Ashton-Rickardt and 
Tonegawa, 1994), T cells in contact with unstable complexes would tend to 
escape negative selection in the thymus. In fact, studies have found that mice 
carrying the H-28? class II molecules contained about 8-fold more autoreactive 
T cells, than their congenic counterparts bearing H-2 MHC (Kanagawa et al., 
1998). This issue remains to be resolved and has important implications not 
only for T cell selection but T cell reactivity in response to antigen 
presentation. The diabetogenicity of the NOD mouse H2g7 MHC haplotype is 
further enhanced by the lack of I-E expression on NOD APC's, due to a 
mutation in the first exon of the Ea gene (Ikegami et al., 1990). IDDM is 
inhibited in the NOD mouse with expression of the I-E transgene derived 
from diabetes resistant MHC haplotypes (Lund et al., 1990; Nishimoto et al., 
1987). 
B. MHC Class I molecules 
Though the role of MHC class I region has been studied less than that 
of class II, it is clear that common class I alleles, such as Kd or Db, encoded by 
* 
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the H2g7 MHC haplotype of NOD mice play an essential role in the 
development of IDDM. As it will be described later, the requirement of MHC 
class I expression was demonstrated following the development of (32- 
microglobulin knock-out ((32m”u//) NOD mice which do not express H-2S7 class 
I molecules, and remain free of diabetes (Serreze et al., 1994). IDDM is also 
inhibited in NOD mice that are congenic for the MHC haplotype of the CTS 
mouse strain, that shares the same MHC class II allele, but not the class I 
allele, of the NOD mouse (Ikegami et al., 1995). Similarly, it has been recently 
demonstrated that certain MHC class I alleles such as HLA-A2 in humans 
may play a role in enhancing IDDM susceptibility (Demaine et al., 1995; 
Fennessy et al., 1994). 
5. The diabetogenic roles of CD4 and CD8 T cells 
Overview 
Diabetes is an ancient disease and is quite prevalent, yet facets of this 
disease are poorly understood, including the immunological mechanisms 
which initiate it. It has been established that IDDM results from a T-cell 
dependent autoimmune process directed against the pancreatic (3 cells, 
however the role of these particular T lymphocyte subsets, and their target 
antigens, remains to be elucidated. 
T cells are important in the pathogenesis of diabetes. Histological 
analysis of islet lesions reveal the presence of both CD4 and CD8 T cells 
(Miyazaki et al., 1985). Injection of anti-CD3 antibodies inhibits disease 
progression (Hayward and Shreiber, 1989). However, the precise contribution 
of CD4 and CD8 T cells to disease progression is uncertain. Several groups 
have shown that both CD4+ and CD8+ T cells from young diabetic donors are 
required for disease transfer into neonatal, irradiated young, or genetically T 
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cell-deficient NOD recipients (Bendelac et al., 1987; Christianson et al., 1993; 
Miller et al., 1988; Rohane et al., 1995) indicating that these cells likely have 
synergistic roles. CD4 T cells alone invade the islets, but diabetes develops 
only in the presence of CD8 T cells. CD8 cells, alone, cannot transfer insulitis 
or diabetes (Christianson et al., 1993; Thivolet et al., 1991). These findings led 
to the notion that CD4 T cells may initiate diabetes, and recruit CD8 T cells, 
the effector cells capable of carrying out the final destruction of islet p cells. 
This idea was consistent with other data, such as the isolation of CD8 T cell 
clones with in vitro and in vivo anti-islet beta cell cytotoxic activity [Reich et 
al, 1989 #40; Nagata, 1989 #474; Hayakawa, 1991 #290; Nagata, 1994 #239; 
Nagata, 1992 #242]. Some studies found that CD4 cells precede the entry of 
CD8 T cells into islets, following the transfer of whole splenocytes from 
diabetic donors into to healthy recipients (O'Reilly et al., 1991). On the other 
hand, others have shown that macrophages and CD8 T cells are the earliest 
infiltrating cells. (Bedossa et al., 1989; Jarpe et al., 1990). 
A. CD8 T cells as initiators of diabetes 
More recently, there is an increasing body of evidence that CD8 T cells 
are important in the initiation of diabetes in addition to playing a cytotoxic 
role in the final stages of P cell destruction. Pancreatic P cells are generally not 
regarded as effective APC's, possessing MHC class I molecules, but not class II 
molecules on their surface (Mclnerney et al., 1991; Signore et al., 1989). 
Therefore, if CD4 T cells are to recognize P cell antigens, they must do so in 
the context of I-A87 molecules on the surface of professional antigen- 
presenting cells (APC's), such as macrophages and dendritic cells residing in 
the pancreatic islets. As such, it seems likely that an initial P cell insult 
occurs, mediated by MHC class I-restricted CD8 T cells, followed by the release 
' 
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of soluble antigens that are then processed and presented by APCs to CD4 T 
cells. An initiating function of CD8 cells would also be more in line with 
human diabetes, where CD8 T cells seem to dominate the islet infiltrate of in 
newly diagnosed patients (Bottazzo et al., 1985; Hanninen et al., 1992; Itoh et 
al., 1993) and are highly activated in the blood (Hehmke et al., 1995). 
B. MHC Class I molecules and the role of CD8 T cells 
The strongest evidence that CD8 T cells may be important in the 
initiation of type 1 diabetes comes from studies in which NOD mice are bred 
to lack functional MHC class I molecules and consequently most CD8 T cells. 
MHC class I molecules consist of a 45 kD polypeptide chain, the alpha chain, 
which is non-covalently associated at the cell surface with [32-microglobulin 
(|32-m). In 1990 it was reported by two groups that following the disruption of 
the [32-m gene by targeted mutation, mice are unable to express |32-m, and 
therefore MHC class I molecules (Koller et al., 1990; Zijlstra et al., 1990). 
However, MHC class II expression and CD4 cells appears normal. 
Consequently, these mice lack virtually all mature CD8 T cells, supporting 
previous evidence that interactions with class I MHC molecules are essential 
for CD8 T cell development (Sha et al., 1988; Zuniga-Pflucker et al., 1989). 
As a means to further examine the relative contributions of MHC class 
I-restricted and MHC class II-restricted T cells to autoimmune pancreatic (3 cell 
destruction, several groups bred NOD mice with (32-m knock-out mice (NOD- 
$2mnull) (j^atz et al., 1993; Serreze et al., 1994; Sumida et al., 1994; Wicker et al., 
1994). It was found that NOD mice deficient in MHC class I expression and 
CD8 T cells, remained completely free of both insulitis and diabetes. These 
results seem to argue that CD8 T cells are crucial for the initiation of diabetes 
in NOD mice. Further evidence of the initiating role of CD8 T cells in 
N 
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diabetes came from studies demonstrating the inhibition of insulitis 
following the injection of anti-CD8 monoclonal antibodies into young NOD 
mice, between 2 and 5 weeks of age (Wang et al., 1996). These results also 
suggest that it is the lack of CD8 T cells, rather than the lack of MHC class I 
molecules, which prevents infiltration of the islets. Finally, supporting 
evidence for the participation of CD8 T cells in disease initiation has come 
from studies demonstrating that T cells from young prediabetic NOD mice 
transfer disease to MHC class I-positive NOD-SCID mice but not to NOD-SCID 
mice bearing the (32mnw^ mutation (Serreze et al., 1997). It is also evident that 
the absence of CD4 T cells, such as with NOD.CD4-/- mice (Wong et al., 1998), 
and following anti-CD4 antibody treatment (Shizuru et al., 1988), prevents 
insulitis and diabetes. Thus, there is a dual role played by CD4 T cells and CD8 
T cells in disease initiation. 
It is important to recognize that the critical role of CD8 T cells in 
initiation of diabetes does not exclude their effector function. The transfer of 
diabetes to NOD-(32mnu^ recipients with diabetic spleen cells is considerably 
delayed compared with wild-type NOD mice (Kay et al., 1996; Wicker et al., 
1994). It is possible that once activated, the CD4 cells in this transfer 
population are able to target and destroy $2mnul1 islet (3 cells. This suggests a 
role for substantial numbers of CD8 T cells in the effector phase of diabetes. 
Likewise, when NOD(32mnu^ mice are made transgenic for (32m on the rat 
insulin promoter (RIP), thus restoring MHC class I expression only on islet |3 
cells, mice rapidly developed diabetes, following the transfer of diabetic spleen 
cells, at the same rate as wild-type NOD recipients (Kay et al., 1996). 
Interestingly, restoration of P-cell MHC class I, without restoring CD8 T cells, 
was sufficient to cause insulitis but not diabetes. This might be explained by 
previous findings that (32m”w^ mice possess small numbers of CD8 T cells 
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which are probably not functional in the absence of MHC class I expression 
(Lehmann-Grube et al., 1994; Zijlstra et al., 1992). In RIP-P2m/NOD(32mnw// 
mice this small population may be able to initiate damage of P cells, yet 
remain too scarce to be involved in the final effector stage of diabetes. 
C. T cell effector mechanisms 
As previously discussed, CD4 and CD8 T cells play a role in both the 
initiation and the effector phase of P-cell destruction. It is not clear however, 
if the requirement for both CD4 and CD8 T cells in diabetes results from their 
synergistic or independent contributions. Furthermore, the mechanisms by 
which P cell destruction by CD4 and CD8 T cells occurs is not well established. 
It seems that CD8 T cell cytotoxicity results from the direct production of the 
effector molecule perforin, and granzymes. These molecules are also able to 
induce programmed cell death, or apoptosis. Apoptosis is also mediated by 
membrane-associated TNF-related molecules, such as Fas ligand, which 
interacts with Fas, its receptor, on target cells. Support for perforin-mediated 
P cell destruction comes from the LCMV-gp model. These mice are made 
perforin-deficient, and when LCMV-gp-specific T cells are activated following 
LCMV viral infection, they do not develop diabetes (Kagi et al., 1996), and 
perforin-deficient NOD mice have delayed onset of diabetes (Kagi et al., 1997). 
On the other hand, recent evidence indicates that apoptosis, as a result of 
Fas/Fas ligand interactions, in the NOD mouse may represent a dominant 
mode of islet P cell destruction by CD8 T cells (Chervonsky et al., 1997). 
Additionally, CD4 T cells have also been shown to destroy P cells. Since P 
cells do not express MHC class II molecules it is generally thought that CD4 T 
cell destruction is mediated indirectly, following their activation by APCs 
bearing P-cell-specific antigens. Alternatively, CD4 T cells could kill P cells by 
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inducing apoptosis. Kurrer et al (1997), using a TCR from the CD4 T cell clone 
BDC2.5, have shown that [3 cells die by apoptosis following interactions with 
BDC2.5 cells, and that death is triggered by a mechanism other than Fas/FasL, 
such as TNFa-TNFR interactions. Islet cells do not normally express Fas, but 
can be induced to up-regulate its levels by IL-1 and interferon-y (IFN-y) (Stassi 
et al., 1996; Yamada et al., 1996). Thus, cytokine production by CD4 and CD8 T 
cells may up-regulate Fas on islets, at which point Fas ligand-expressing CD8 
T cells and CD4 cells would induce apoptosis (Wong and Janeway, 1997). 
In earlier studies with NOD mice, investigators in our laboratory 
generated NOD mice that express the B7-1 co-stimulatory molecule, using the 
rat insulin promoter-1 (RIP), on pancreatic (3 cells. At the first backcross to 
NOD, mice homologous to the NOD MHC develop accelerated diabetes, with 
more than half the animals developing diabetes before 12 weeks of age. 
Under normal circumstances (3 cells do not express costimulatory molecules 
(Stephens and Kay, 1995). In this NOD-R1P-B7-1 model, it appears as though 
B7-1 expression allows (3 cells to be effective APC's. They become potent 
stimulators of CD8 T cells that are specific for |3 cell antigens presented by 
MHC class I molecules. Interestingly, both CD4 and CD8 T cells are required 
for the acceleration of diabetes in this model (Susan Wong et al., 1998). 
It remains a possibility that T-cell activation in NOD mice does not 
require costimulation with B7 and could result from the interaction of CD8 T 
cells with B7-negative (3 cells. It is hypothesized that CD8 T cells are activated 
outside the pancreas in surrounding lymph tissue, where they recognize their 
antigen in the context of a costimulatory signal on the surface of APC's. 
These activated cells could then recognize their antigen within islets without 
the need of direct costimulation by B7 molecules (Wong and Janeway, 1997). 
There is increasing evidence that B lymphocytes may play a critical role in the 
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induction of diabetes, since their depletion causes resistance to both diabetes 
and insulitis (Noorchashm et al., 1997; Serreze et al., 1996). This effect likely 
relates to the ability of B cells to present antigen and costimulate T cells. On 
the other hand, it has recently been shown that dendritic cells, but not 
macrophages, efficiently present antigens derived from apoptotic cells which 
can then stimulate MHC class-I-restricted cytotoxic CD8 T cells (Albert et al., 
1998). This may represent an exogenous pathway for CD8 T cell activation 
against target islet (3 cell antigens. 
D. Diabetogenic CD4 and CD8 T cell lines and clones 
With the advent of cloned T cell lines, it seemed that information on 
the relative contributions of CD4 and CD8 T cells to (3 cell destruction, as well 
as interactions between the two populations might be further delineated. 
However, the diabetogenicity of various lines and clones is apparently quite 
variable (Table 1). In addition, the requirement for both T cell subsets to cause 
diabetes is not as clear when T cell clones are used. In some reports, CD4 T 
cell clones can transfer disease but require the presence of CD8 T cells (Nagata 
et al., 1994; Pankewycz et al., 1991; Reich et al., 1989; Shimizu et al., 1993). On 
the other hand, several groups have isolated CD4 T cell clones (Daniel and 
Wegmann, 1996, Zekzer, 1997 #485; Peterson and Haskins, 1996) reactive to 
islets or known islet antigens, which can transfer diabetes in 4-7 weeks in the 
absence of other cells. 
CD8 T cell clones are difficult to isolate, and consequently there are 
fewer reports of islet-specific CD8 T cell clones than there are CD4 clones. In 
addition, investigators have generally not observed disease transfer when 
CD8 clones are used alone, but only when they are cotransferred with CD4 
lines or spleen cells (Nagata et al., 1994; Santamaria et al., 1995; Verdaguer et 
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al., 1996). Other researchers (Shimizu et al., 1993) isolated CD8 T cell clones 
from pancreatic islets of NOD mice which did not transfer disease even in the 
presence of CD4 T cells. However, investigators in our laboratory have 
recently generated an islet-specific CD8 T cell clone which has the capacity to 
cause diabetes rapidly (within 10 days) when transferred to irradiated NOD, 
young NOD-SCID, and CB-17-SCID mice, in the absence of CD4 cells (Wong et 
al., 1996). 
These diabetogenic CD8 T cell clones were isolated from the pancreatic 
islets of young 7 week old NOD mice, which have insulitis but are not yet 
diabetic. They differ from other CD8 T cell clones in that they were grown on 
islets from B7-1 -expressing (NOD X C57BL/6J-RIP B7-1)F1 hybrid mouse cells 
are highly cytotoxic, and express IFN-y, TNF-a, TNF-J3, and the effector 
molecule perforin. They rapidly destroy pancreatic islets in recipient NOD 
mice that do express B7-1 in their pancreases, indicating that B7-1 is not 
required for specific recognition or final effector function (Wong et al., 1996). 
It has previously been demonstrated that T cells, capable of targeting 
and damaging islets, are present in the islets of young, pre-diabetic NOD mice 
(Rohane et al., 1995). It is important to note that these cells are highly 
cytotoxic, and express IFN-y, TNF-a, TNF-(3, and the effector molecule 
perforin. They rapidly destroy pancreatic islets in recipient NOD mice that do 
express B7-1 in their pancreases, indicating that B7-1 is not required for 
specific recognition or final effector function (Wong et al., 1996). It is 
important to note that the CD8 T cell clone isolated by Wong and colleagues 
(1996) was isolated from 7 week-old mice that had insulitis but would not be 
diabetic for several weeks. Therefore, these cells may represent a population 
of cells capable of inflicting significant damage to islets, and may be 
contributing to the initiation of the autoimmune process. 
, 
18 
6. Autoantigens in type 1 Diabetes 
Studies of NOD mouse from the neonatal period through to diabetes 
onset has led to view that the diabetogenic process is a step-wise development 
marked by two proposed 'checkpoints' (Andre et al., 1996). The first is seen at 
about 4-6 weeks of age, and is characterized by peri-insulitis. Following this, 
there is direct invasion of the islets by infiltrating cells, or intra-insulitis, 
which is dependent on recognition of P cell antigens (Wicker et al., 1992). A 
temporal analysis of P cell reactivity suggests that a few autoantigens are 
targeted early in insulitis (Kaufman et al., 1993; Tisch et al., 1993), and that 
intra-insulitis results in the recruitment of additional P-cell reactive T cells in 
the periphery. The onset of diabetes at 18-20 weeks represents the second 
checkpoint, and does not seem to be driven by insulitis per se (Katz et al., 
1993). These events may depend on changes in regulatory and effector T cells, 
or possibly a cascade of antigen recognition, or both. 
It has been about a decade since the identity of most known p cell 
autoantigens were determined. Despite this progress, many questions 
remained unanswered, particularly the intriguing question of whether a 
dominant, initiating antigen exists, and what is its nature. The roles of 
known P cell antigens are poorly understood, including whether they are in 
fact pathogenic. Particular P cell antigens in IDDM have been studied by first 
correlating autoantibody reactivity, and T cell reactivity, with disease 
progression in both human and NOD mice, and secondly looking at how 
diabetes in the NOD mouse can be modulated following antigen 
administration or transfer of antigen-specific T cell clones. 
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A. Glutamic acid decarboxylase 
The above criteria have been used to characterize glutamic acid 
decarboxylase (GAD) as a critical (3-cell autoantigen. Its two isoforms, GAD65 
and GAD67, are the enzymes that catalyze the formation of the 
neurotransmitter, y-aminobutyric acid. Autoantibodies to a 64 kilodalton (kd) 
protein were found to be present in diabetic patients in the 1980s (Baekkeskov 
et al., 1987). This antigen was subsequently identified as GAD, and is now 
used as a predictive marker in pre-diabetic patients (Baekkeskov et al., 1990; 
Hagopian et al., 1993). In the NOD mouse anti-GAD T cell responses appear 
very early on in insulitis, and prior to the appearance of T cell reactivities to 
other (3 cell antigens (including HSP60, and carboxypeptidase H) (Kaufman et 
al., 1993; Tisch et al., 1993). Thus anti-GAD activity may be connected to early 
events associated with insulitis. Furthermore, NOD mice are protected from 
diabetes when they are immunized early on with GAD (Elliott et al., 1994; 
Zechel et al., 1998) and seem to undergo a shift from a Thl-like response to a 
Th2-like GAD67-specific response. It has also been demonstrated that NOD 
mice exhibit spontaneous T cell reactivity to GAD (Kaufman et al., 1993; 
Quinn and Sercarz, 1996; Tisch et al., 1993). GAD-specific CD4 T cell clones 
have been generated (Schloot et al., 1996), and one such T cell clone has been 
shown to cause diabetes in NOD-scid mice (Zekzer et al., 1998). On the other 
hand, nasal administration of GAD was found to prevent diabetes, and down- 
regulate T-cell reactivity (Tian et al., 1996). Thus further work is needed in 
order to determine the relative contribution and precise role of anti-GAD 
reactivity in the disease process. 
\ 
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C. Insulin 
Insulin is secreted, and along with C-peptide, comprises about 80% of 
the (3-cell protein (Hutton, 1989). Thus its role as an autoantigen has been of 
great interest. It has been studied extensively and in fact appears to play an 
important role in diabetogenesis. Antibodies to insulin are found in about 
half of recent-onset diabetic subjects, and occur most frequently in children 
who have more aggressive (3-cell destruction (Castano and Eisenbarth, 1990). 
The first report of insulin-reactive T cell clones was by Wegmann et al 
(Haskins and Wegmann, 1996), who isolated CD4 T cell lines and clones from 
7 and 12 week old NOD mice, following their culture with islet cells as 
antigen. Of the CD4 T cell clones isolated from younger mice 14% of the cells 
were reactive to insulin. However, about half of the clones isolated from the 
older mice were insulin-reactive, the majority of which expressed a Thl-like 
phenotype, and one clone was found to transfer diabetes to NOD-scid mice. 
Most of these CD4 T cell clones respond only to the insulin B chain (Daniel et 
al., 1995), and NOD mice have shown diabetes resistance following the 
administration of this dominant epitope (Daniel and Wegmann, 1996; Muir 
et al., 1995). Unlike young NOD mice treated with GAD, histologic 
examination of mice receiving insulin continued to exhibit insulitis, which 
suggests that insulin reactivity correlates with a later phase of disease 
progression. More recently it was shown that the proinsulin II gene driven 
off the MHC class II promoter, to direct expression of proinsulin to MHC class 
ITbearing cells particularly in the thymus, almost completely prevents 
insulitis in transgenic NOD mice (French et al., 1997). Therefore, proinsulin 
also appears to play an important role in the pathogenesis of diabetes. 
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C. Other [5-cell autoantigens 
Several other p-cell proteins have been identified as T cell antigens. 
Autoantibodies and T cell reactivity directed towards heat shock protein 
(HSP) have been detected in NOD mice (Elias et al., 1990), and HSP60 reactive 
CD4 T cell clones were found to induce disease in NOD mice (Elias et al., 
1991). However, it is not clear whether HSP is a target in human IDDM. 
Other target (3-cell autoantigens identified in humans include 
carboxypeptidase H, islet-cell antigen (ICA) 69, and the tyrosine phosphatase 
IA-2/ICA512, found in the (3-cell granule membrane. ICA512 is an important 
though less known ICA (Solimena et al., 1996), and anti-GAD and anti- 
ICA512 antibodies together are strongly predictive of diabetes in first degree 
relatives of diabetic patients (Bingley et al., 1997). 
With the exception of insulin and proinsulin, few other molecules 
which are limited in their expression to (3 cells, have been well characterized 
(Hutton, 1989). However, evidence for an undefined membrane-associated 
antigen has been provided for CD4 islet-specific T cell clones (Bergman and 
Haskins, 1994). Subcellular locations of islet antigens were analyzed, and it 
was found that a fraction which was highly enriched in (3-cell granules was 
antigenic for every T cell clone tested. They subsequently localized that 
activity to the (3-cell granule membrane. 
Many important questions regarding the nature and role of (3-cell 
autoantigens remain to be answered. At present it seems that rather than a 
single, organ specific antigen, many antigens play a role in human IDDM and 
NOD mice, and many more unidentified (3-cell autoantigens likely exist. One 
important unanswered question is whether there exists a primary P-cell 
antigen that dominates the induction of diabetes, and if it does exist, will its 
identification have therapeutic implications? It seems unlikely that the 
I 
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various autoantigens identified thus far could be initiating the same primary 
diabetogenic response. Rather, it is likely that a particular type of antigen is 
responsible for disease initiation, leading to local inflammation, and 
recruitment to the pancreas of islet-reactive T cells with more diverse 
specificities (Haskins and Wegmann, 1996). 
To date, research has focused on the generation of CD4 T cell clones 
that are reactive to previously identified P cell autoantigens. As discussed 
above, it now appears that CD8 T cells may be critical initiators of diabetes. 
Thus, it is likely that the antigenic targets of CD8 T cell also contribute to 
IDDM induction. However, no CD8 T cell antigen has yet been identified in 
human or NOD mouse IDDM. Elucidating the nature of CD8 T cell 
autoantigens is important for further understanding IDDM in NOD mice and 
humans, developing treatment modalities, and may lead the discovery of a 
dominant primary diabetogenic antigen. 
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Table 1. T cell clones from the NOD mouse (table adapted from Bergman and 
Haskins, 1997). 
Origin of T cells CD4/CD8 Antigen 
specificity 
in vivo activity Investigators 
Spleen and lymph nodes 
of diabetic females 
CD4 Islet cells, (3 
granule 
membrane 
Insulitis & 
diabetes 
Haskins et al, 1988, 
1989. Bergman & 
Haskins 1994 
Islet infiltrates of 
diabetic females 
CD4 &CD8 Islets cells Insulitis Reich et al, 1989 
Islet infiltrates of 
diabetic females 
CD4 Unknown Protection Reich et al, 1989 
Islet infiltrates of 20- 
week old pre-diabetic 
females 
CD8 Islet cells Not determined Nagata et al, 1989 
Three month old female CD4 HSP-65 Insulitis Elias et al, 1990 
Islet infiltrates of 8- 
week females (ND)a 
CD4 Islet cells Protection Pankewycz et al, 
1991 
Islet infiltrates of 8- 
week females (ND) 
CD8 Unknown Insulitis Pankewycz et al, 
1991 
Islet infiltrates of 7-10 
week old mice (ND) 
CD4 Islet cells Insulitis Nakano et al, 1991 
Islet infiltrates of <10 & 
> 10 week old females 
(ND) 
CD4 & CD8 Islet cells Diabetes (CD8 
co-transferred 
with CD4) 
Nagata and Yoon, 
1992. Nagata et al, 
1994 
Islet infiltrates from 
irradiated male 
recipient 
CD4 & CD8 Islet cells Diabetes (CD4 
clones only 
Shimizu et al, 1993 
Islet infiltrates of 10-12 
week old females (ND) 
CD4 Unknown Not determined Maugendre et al, 
1993 
Islet infiltrates of 4- 
week old females (ND) 
Not 
determined 
Unknown Protection Chosick & 
Harrison, 1993 
Infiltrated islet 
allographs 
CD4 Islet cells Insulitis and 
diabetes 
Wegmann et al, 1993 
Islet infiltrates of 4 & 7 
week old females (ND) 
CD4 Islet cells, 
insulin 
Insulitis and 
Diabetes 
Wegmann et al, 1994 
Spleen & lymph nodes of 
30-40 day old females 
(ND) 
CD4 Insulinoma 
extracts 
Insulitis Gelber et al, 1994 
Lymph nodes of 6-week 
old or diabetic females 
CD4 GAD-67 Not determined Elliot et al, 1994 
Lymph nodes of diabetic 
females 
CD4 Islet cells Insulitis and 
Diabetes 
Healey et al, 1995 
Spleen cells of 4-week 
nondiabetic females 
CD4 Islet cells Protection Akhtar et al, 1995 
Islet infiltrates of 7 
week old females (ND) 
CD8 Islet cells Diabetes Wong et al, 1996 
Spleens of 6 week old 
diabetic mice, 
previously immunized 
with GAD 
CD4 Islet cells Insulitis and 
Diabetes 
Zeckzer et al, 1998 
a ND; Non-Diabetic 
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7. Measuring T Cell Activation 
Overview 
T cell activation takes place when a TCR of a circulating lymphocyte 
discovers and binds to its peptide/MHC ligand. Many biochemical events, 
both cytoplasmic and nuclear take place during T cell activation (Cantrell, 
1996). Early cytoplasmic events such as protein tyrosine kinase cascades, 
cleavage of inositol phosphate by phospholipase C, and the mobilization of 
intracellular calcium stores, lead to the expression of numerous genes 
required for T cell proliferation and effector functions. Transcription of the 
interleukin II (IL-2) gene occurs early on in T cell activation, and in fact is 
thought to be the first committed step of the activation pathway (Crabtree, 
1989). Following antigen recognition by the TCR, a transcription factor called 
nuclear factor of activation in T cells (NFAT) binds to the promoter region of 
the IF-2 gene. The NFAT binding site (Figure 2) is believed to be the most 
important response element for TCR-mediated transcription of the IF-2 gene 
(Shaw et al., 1988). 
A. Bulk T cell activation assays 
The detection and quantitation of T cell activity, and thus any 
experimental strategy aimed to identify the peptides recognized by 
immunologically important TCRs, has been hampered by the fact that most 
T-cell activation assays have low sensitivities. Measuring cytotoxic T cell 
activity in vitro includes such techniques as 3H-thymidine proliferation 
assays, or in the case of cytotoxic T cells, quantifying killing of target cells via 
51Cr-release assays. Assays which quantitate lymphokine production, 
including the IF-2, TNF, and INF-y assays, are commonly used. More 
recently, the development of calcium sensitive dyes has enabled the 
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visualization of calcium mobilization during T cell activation (Poenie et al., 
1987). However, calcium fluxes do not always correlate with T cell activation, 
and so calcium levels are not as reliable measure of T cell activity as are the 
IL-2, proliferation, and cytoxicity assays (Sussman et al., 1988). 
These assays provide a rapid and specific measurement of cytotoxic T 
cell activity, yet they have a significant drawback. With the exception of 
calcium sensitive dyes, these T cell activation assays detect compounds 
released by T cells or APCs into the supernatent, and thus measure the 
average activation state of all T cells in the assay. They provide no 
information regarding the activation state of individual T cells, and cannot be 
used to detect activated T cells when they form only a small proportion the 
total T cell population being assayed. This limits the sensitivity of bulk T cell 
activation assays for detecting peptide/MHC-expressing APCs . 
B. NFAT lacZ reporter construct and the lacZ assay 
In this thesis we have taken advantage of a recently introduced T cell 
activation assay (Karttunen and Shastri, 1991), which utilizes a reporter 
construct consisting of the bacterial lacZ gene under control of the NFAT 
element of the human IL-2 enhancer (Figure 2). The lacZ gene encode (3- 
galactosidase, an enzyme that acts on chromogenic substrates such as 5- 
bromo-4-chloro-3-indolyl-(3-D-galactopyranoside (X-gal). LacZ activity is 
induced in T cells by the interaction with peptide/MHC ligand, and parallels 
IL-2 expression. Once activated, T cells transfected with the lacZ reporter 
express uniformly high levels of (3-gal and turn blue in the presence of X-gal. 
This enables the detection of individual activated cells, even when they are a 
small fraction of the total T cell population. This additionally allows for the 
detection of rare APCs which express the activated T cell's target antigen. 
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8. Strategies for identifying T cell antigens 
Overview 
There are two general strategies for the identification of the peptide- 
MHC ligands recognized by T cells: biochemical purification of MHC-bound 
processed peptides, and expression cloning of the antigenic genes. Both 
approaches require that the MHC-peptide ligand be expressed on the surface 
of APCs, and be detectable by a T cell activation assay. 
A. Biochemical purification of antigens 
T cell antigens can theoretically be identified by directly purifying 
naturally processed and presented MHC-bound peptides from target APCs. 
However, biochemical purification is difficult not only because MHC 
molecules display thousands of different peptides on the cell surface (Falk et 
al., 1991; Hunt et al., 1992), but also because only a few copies of individual 
antigenic peptides may be presented per cell (Cox et al., 1994; Kageyama et al., 
1995). In addition, it is noteworthy that the peptide purification strategy 
requires sophisticated instrumentation, (such as a high pressure liquid 
chromatography (HPLC) system and a mass spectrophotometer), not to 
mention experimental and analytic skills that are not available in many 
laboratories. 
Nevertheless, several groups have overcome these difficulties and 
have identified the antigenic ligands of some T cells using HPLC. Eisen and 
co-workers identified the peptide component of the 2C ligand alloantigen 
(graft rejection antigen) recognized by C57BL/6 T cells on BALB/c mouse 
tissue (Udaka et al., 1992; Udaka et al., 1993). A human alloantigen associated 
with HLA-A2.1 class I molecule (Henderson et al, 1993), as well as a peptide 
recognized by melanoma-specific human cytotoxic T cell lines (Cox et al.. 
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1994), were similarly isolated by Hunt and colleagues. However, unlike 
alloantigens and tumor cell proteins which can be relatively abundant, most 
immunologically important peptides, including those involved in 
autoimmunity, are present at very low frequencies on cell surfaces, and have 
been resistant to isolation by this approach. 
The identification of autoantigens in type 1 diabetes using biochemical 
analysis is particularly difficult because the isolation of mouse islets is a very 
expensive and labor intensive endeavor. The typical yield from a NOD 
mouse pancreas is in the order of 105 islet cells. Thus the biochemical 
purification of islet cell proteins, which requires in the order of 1010'12 islet 
cells (Shastri, 1996), is not feasible without a tumor cell source. 
Unfortunately, tumor cell lines are known to undergo a variety of changes 
when kept in culture, and tend to quickly lose their antigenicity. Researchers 
who have attempted to identify T cell antigens using biochemical techniques 
have thus needed to use mouse strains that produce (3-cell tumors 
(insulinomas) (Bergman and Haskins, 1997). However, this antigenic source 
may similarly not be representative of the proteins naturally existing in NOD 
mouse islets. 
B. Expression cloning of T cell antigens 
In contrast to biochemical purification, expression cloning strategies are 
not dependent upon the total amount of obtainable peptide, but upon the 
construction of representative cDNA libraries, the efficient expression of 
candidate antigen genes, and the generation of appropriate peptide-MHC 
ligands on the APCs. The much smaller amounts of tissue required to make 
a cDNA library, as compared to the amount needed to purify adequate 
quantities of peptides, is especially useful when antigen-expressing tissue, as 
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with the pancreatic islets of NOD mice, is particularly difficult to obtain. Not 
only does this approach require less starting materials, the DNA 
manipulations required for expression cloning are now routinely available in 
most laboratories (Shastri, 1996). For these reasons we have chosen to use 
expression cloning, rather than peptide purification as a means to identify the 
islet cell antigen of our diabetogenic CD8 T cell clones. 
C. Expression cloning of a CD8 T cell antigen 
The isolation of CD8 T cells and identification of their autoantigenic 
peptides is a difficult task. Thus very few CD8 clones have been generated, 
and their target antigens have remained elusive (Nagata et al., 1994; 
Santamaria et al., 1995; Shimizu et al., 1993). The primary difficulty with 
identifying T cell antigens, which relies on the detection of ligand-induced T 
cell activation, arises from the fact that neither the TCR nor its peptide/MHC 
ligand exist functionally in a soluble state. Since both the receptor and its 
ligand are membrane-bound, screening for a T cell antigen must rely on 
cellular assays, the majority of which are inherently insensitive, and cannot 
detect small populations of activated T cells. The work of Jaana Karttunen in 
developing the LacZ assay further suggested an expression cloning strategy 
that exploits the highly sensitive lacZ inducible T cell hybrids (Karttunen et 
al., 1992; Sanderson and Shastri, 1994). This cloning strategy, originally 
developed by Aruffo and Seed, is based on the transient expression of 
candidate cDNAs in COS cells (Aruffo and Seed, 1987a, 1987b). 
COS cells are transformed cell lines generated by the transfection the 
CV-1 simian fibroblast line with an origin defective mutant of the SV40 virus 
(Gluzman, 1981). These cell lines stably express the SV40 large T antigen. As 
such they are capable of replicating circular DNAs containing the SV40 origin 
_ 
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of replication, and attain very high levels of protein expression. Using the 
lacZ assay, it has been shown that COS-7 cells can function as APCs for the 
detection of rare antigens found in the primary screen of expression libraries; 
antigen-expressing COS-7 cells can be detected at frequencies of 1:103 to 1:104 
(Karttunen et al., 1992). Since T cells recognize peptide in the context of self- 
MHC molecules, COS cells must first be stably transfected with the relevant 
MHC molecule. 
We are applying this expression cloning system as a means to identify 
the nature of the antigen recognized by the CD8 cell lines in young NOD mice 
(Wong et al., 1996). The system consists of lacZ inducible T-cell hybrids 
specific for the unknown antigen, and a COS cell line expressing the relevant 
MHC. In this case the H-2Kd restriction element recognized by the CD8 T cell 
clones has been stably transfected into COS-7 cells (Kd-COS). These APCs, in 
the presence of lacZ inducible hybrids, were used to screen a cDNA library 
that was generated from normal islet (3 cells which express the autoantigen 
(Figure 3). 
Statement of purpose 
The definitive identification of the autoantigens involved in IDDM is 
an important initial step in sorting out the series of events leading to the 
acquisition of the disease. Despite significant efforts to identify the specific 
antigenic peptide recognized by an individual TCR, this has remained a 
difficult undertaking. The primary reason for this difficulty lies in the 
inherent lack of sensitivity of the bulk T-cell activation assays used to detect 
peptide/MHC-expressing APCs. These assays only measure the average state 
of activation within a given T cell population, and thus cannot detect 
activated T cells when they constitute only a small percentage of the total T 
1 
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cells being assayed. The research presented here is the screening of an 
expression cDNA library made from normal NOD mouse islets which express 
the autoantigen of cloned CD8 T cells, obtained at an early stage of disease in 
NOD mice. This requires the ability to detect ligand-bearing APCs when they 
are present at very low frequencies. In recent years a method for detecting 
individual ligand-activated T cells that are stimulated by correspondingly rare 
MHC class I restricted APCs has been developed. This method has been used 
here as an expression cloning strategy for identifying the target antigen(s) of 
the diabetogenic G9 CD8 T cell clone. 
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Islet cDNA 
Plasmid expression vector 
SV40 replication origin 
Kd 
Kd COS cell 
Kd + peptide 
Figure 3. Schematic illustration for processing and presentation of transiently 
expressed proteins by Kd-COS cells to the BW/G9 T-cell hybrid. 

33 
Materials and Methods 
1. Cell culture 
COS-7 cells (ATCC) are maintained on Dulbecco's minimum essential 
medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM 
glutamine, 1 mM pyruvate, penicillin (200 units/ml), streptomycin (200 
ug/ml), and streptomycin (200 fig/ml). Kd-COS cells were maintained on 
DMEM with supplements, plus 1 pg/ml G418 (Geneticin). T cell hybrids are 
maintained on Click's with 10% fetal bovine serum, plus antibiotics. All cells 
are kept at 37°C in a 9% C02/91% air atmosphere. 
2. Cell lines. 
As indicator T cells, this system uses a-P-BW5147 cells, transfected with 
the NFAT-/acZ construct by electroporation (obtained from Dr. N. Shastri). 
These cells were transfected with a CD8a retrovirus and have been fused to 
the diabetogenic CD8 T cell clone G9 (Wong et al, 1996), generating hybrid 
BW/G9 cells which express the V(36 TCR as well as CD8 and CD3, together 
with the lacZ gene driven by the NFAT promoter. 
COS-7 cells were obtained from ATCC. The cells were stably transfected 
with a genomic clone of the murine H-2Kd molecule, kindly provided by J. 
Karttunen (Yale University School of Medicine). Using the Superfect 
transfection reagent (see below), COS-7 cells were transfected with Kd plasmid 
along with a co-selection marker pMCllneo-polyA+ plasmid which confers 
neomycin resistance. Transfectants were selected in 1 jag/ml of G418 
(Geneticin), and Kd expressing COS cells were isolated by fluorescence- 
activated cell sorting (FACS). The most highly expressing Kd~COS cells were 
selected and subsequently cultured. 
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3. Transfection protocols 
COS-7 cells were transfected using Superfect (Quiagen) which 
represents a new class of polycationic transfection reagent, and offers high 
efficiencies and reproducibility, with minimal toxic effect. Stable or 
permanent transfection was carried out using adherent COS cells that were 
50% confluent in 50 ml tissue culture flasks. 10 pg of DNA, complexed with 
Superfect, was transferred to the COS cells. The cells and complexes were 
incubated for 2 to 3 hours at 37°C in 5% CO2 atmosphere. They were then 
washed 4 times with 10 ml of PBS, covered with fresh growth medium, and 
incubated for 24 hours. Transfectants were subsequently selected with 0.5 
pg/ml G418 for 24 hours, followed by 1 pg/ml G418. 
The same protocol was used for transient transfections, though it was 
modified for use in flat-bottomed 96-well plates. Approximately 1 x 104 Kd- 
COS cells per well were plated the day prior to transfection. For each plate, 35 
pg of DNA and 150 pi of Superfect reagent was allowed to complex in 750 pi of 
antibiotic and serum free DMEM. Following incubation, this mixture was 
brought to a total volume of 6 ml with appropriate medium, and 50 pi of the 
mixture was then dispensed into each of the 96 wells of washed Kd-COS cells. 
The cells and DNA-Superfect complexes were incubated for 2-3 hours at 37°C 
in 5% CO2 atmosphere, washed 3 to 4 times with 150 pi of sterile PBS and 
then covered with 100 pi of growth medium per well. Plates were incubated 
for 48 hours before being assayed for lacZ activity. 
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4. FACS staining 
Kd-COS cells were stained for FACS analysis using the monoclonal 
antibody HB159 (anti-H-2Kd). About 105 transfected cells, and untransfected 
control COS-7 cells, were each incubated in the dark for 30 minutes at 4°C 
with the primary HB159 antibody (diluted 1:200). Cells were then spun at 2000 
rpm for 5 minutes, washed once with staining buffer, and respun. The 
secondary antibody, anti-mouse IgG (FC specific) FITC (diluted 1:500), was 
then added to the cells, which were again incubated for 30 minutes in the cold 
and dark. Finally, the stained cells were spun down and fixed with 1% 
paraformaldehyde. 
5. cDNA library construction 
The cDNA library of NOD mouse islet [3 cells, containing the mRNA of 
the unknown peptide, was made using 12 jug of NOD islet mRNA. The 
mRNA was extracted from the islets of 200 young male NOD mice (work 
performed by M. Altieri). The islets were isolated by collagenase digestion 
and purified on Percoll density gradients. Total RNA was extracted using 
Trizol reagent (Gibco) and mRNA was further purified using a poly A 
column (carried out by S. Wong). The cDNA library is an unamplified 
library, and consists of > 3 x 107 primary transformants, which are DH10B 
bacterial cells. The library was provided in sixty, 1 ml pools each containing > 
5 x 105 clones (synthesized by Edge Biosystems AGTC, Maryland). The library 
was constructed in the expression vector pEAX, which contains the SV40 
origin of replication for plasmid expression in SV40 large T antigen¬ 
expressing COS cells (Figure 4). The average cDNA insert size is 1.31 
kilobases, and the insert cutoff size is 700 base pairs. 
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Sequence flanking cloning site of pEAX 
2701 CTGAAGTTAG GCCAGCTTGG CACTTGATGT AATTCTCCTT GGAATTTGCC 
2751 CTTTTTGAGT TTGGATCTTG GTTCATTCTC AAGCCTCAGA CAGTGGTTCA 
2801 AAGTTTTTTT CTTCCATTTC AGGTGTCGTG AA AAGCTT GA ATTC GGCGCG 
Hind III EcoR I Asc I 
2851 CCA GATATC A CACGTG CCAA GGGGCTGGfcDNA 5'- 3'}CA CCTGGCCTGC 
EcoR V Pml I Bst XI 
AGGCGGCCGC 
Not I 
2900 AGGTAAGCCA GCCCAGGCCT CGCCCTCCAG CTCAAGGCGG GACAGGTGCC 
2951 CTAGAGTAGC CTGCATCCAG GGACAGGCCC CAGCCGGGTG CTGACACGTC 
3000 CACCTCCATC TCTTCCTCAG GTCTGCCCGG GTGGCATCCC TGTGACCCCT 
3051 CCCCAGTGCC TCTCCTGGCC CTGGAAGTTG CCACTCCAGT GC 
Figure 4. pEAX vector of the islet cDNA library, and the sequence cloning site 
of pEAX. 
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6. COS cell transient expression assay 
Individual cultures of H-2Kd-COS cells, transiently transfected with 
pools of cDNA, were set up in 96-well plates. The cells were incubated for 48 
hours to allow expression of the introduced genes. After 24 hours, about ten 
NOD mouse islets were added to each of ten wells of the negative control 
plate (see below). Another 24 hours later, 2 X 104 G9 T cell hybrids per well 
were added to the transfected COS cells to give a total volume of 0.2 ml per 
well. 
The T cell hybrids were co-cultured overnight with cDNA-expressing 
Kd-COS cell, and then fixed and stained with 5-bromo-4-chloro-3-indolyl-(3-D- 
galactopyranoside (X-gal) (Sigma). Plates were washed once with 0.1 ml of 
PBS per well, spun for 1 minute at 2000 rpm, and then fixed for 5 minutes on 
ice with 0.1 ml of ice-cold 2% formaldehyde/0.2% gluteraldehyde in PBS per 
well. After another wash with PBS and spinning, the cells were overlaid with 
a solution of 0.5 mg/ml of X-gal, 5 mM potassium ferrocyanide, 5 mM 
potassium ferricyanide, and 2 mM MgCl2. After an overnight incubation at 
37°C, the plates were then examined microscopically for blue (lacZ - 
expressing) hybrid T cells. 
7. cDNA Library Screening. 
Having generated both the expression library and indicator T cells, 
large pools of cDNA's were screened for autoantigen-expressing APCs. This 
method has been shown to detect ligand-expressing APC's at minimum 
frequencies of 1 in 103 (Karttunen et al., 1992). Large pools containing 5 x 105 
cDNAs were initially screened. Since NFAT-mediated transcriptional activity 
is an early event in T cell activation, the lacZ response is detectable within 6 
hours. 
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Controls were included in each set of transfection assays. Negative 
controls consisted H-2Kd COS cells transfected with P022, the DNA sequence 
of ovalbumin. T cell hybrids, incubated with irradiated NOD mouse islets 
and control-transfected COS cells for 24 hours, served as positive controls. 
When wells contained clusters of blue cells, or a significantly greater number 
of blue cells in a well than the negative control plate, they were treated as 
potentially positive pools; that is, the cluster of blue hybrids had been 
activated by a peptide presented by the transfected COS cells. 
Each potentially positive pool was further tested for the presence of an 
activating message using the process of limited dilution (Figure 5). After 
several subdivisions a pool with approximately 200 cDNAs was obtained. 
From these small pools, the plasmid cDNA from single, hand-picked bacterial 
colonies were purified and transfected into single wells of Kd-COS cells. 
When individual cDNA plasmids expression in Kd-COS cells led to the 
activation of significant numbers of BW/G9, the cDNAs were identified as 
candidate antigens. In order to define their nature they were sequenced, and 
compared to known gene and amino acid sequences using the NCBI database 
and Swiss protein database, respectively. Subsequently, the minimal peptide 
determinants within these sequences were identified by comparing them to 
Kd-specific motifs (Falk et al., 1991), which are defined by a tyrosine residue at 
position 2, and leucine or isoleucine at position 9 of the peptide. These 
sequences are then used to synthesize the minimal peptides. The 
antigenicity of these peptides was subsequently evaluated using proliferation 
and 51Cr cytotoxic assays with G9 T cell clones, as well as in LacZ assays with 
Kd-COS cells and BW/G9 hybrids. 
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Figure 5. Schematic illustration summarizing the strategy for expression 
cloning of T-cell antigens. 

40 
8. cDNA pool subdivision 
Pool subdivisions were accomplished by transforming XL-1 blue 
electroporation-competent cells (Stratagene, California). The original 60 pools 
each contained 5 x 105 cDNAs in bacteria. Xl-1 blue cells were transformed by 
electroporation with DNA such that ten fold fewer (ie. 5 x 104) colony forming 
units (CFUs) each receiving a different cDNA plasmid, grew on each of ten 15 
cm x 15 cm Luria-Bertani (LB) agar containing 40 pg/ml ampicillin plates. 
The XL-1 blue cells were thawed on ice, of which 40 pi was mixed with diluted 
DNA. Cells were transferred to a chilled 0.4 cm-gap electroporation cuvette, 
and pulsed once with 2500 volts on a Bio-Rad electroporator, set at a 
resistance of 200 Ohms and capacitance of 25 pF. 960 pi of LB was immediately 
added to the cells, which were then allowed to recover for 1 hour at 37°C 
before being plated (96 pi/plate) as described above. 
Bacterial colonies were scraped off the plates, resuspended, and plasmid 
DNAs purified using the TENS mini-prep method for use in subsequent 
transfections of H-2Kd COS cells. Since the pools were ten-fold smaller, they 
were screened with the lacZ assay in only a third of a 96-well plate. This 
process of limited dilution was repeated each time a positive signal was 
identified in a subdivided pool. 
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Results 
1. Stable transfection of COS cells with the H-2K^ MHC class I 
molecule yields Kd expressing APCs. 
In order to screen the islet cell cDNA expression library, we took 
advantage of the well-developed transient expression system present in COS- 
7 cells (Aruffo and Seed, 1987; Aruffo and Seed, 1987) as described by 
Karttunen and Shastri (1991). COS cells are transformed cell lines generated 
by transfecting the CV-1 simian fibroblast line with an origin-defective 
mutant of the simian virus 40 (SV40). These cell lines express the SV40 large 
tumor antigen and support the replication of circular DNA containing the 
SV40 origin. 
In order to generate a COS cell line that can present peptides/Kd ligands 
to the Kd class I MHC-restricted T cell hybrids, COS cells were stably 
transfected with the Kd molecule. The Kd-expressing COS cells (Kd-COS) were 
analyzed by flow cytometry and found to express Kd at high levels (Figure 6). 
Though the ability of Kd-COS cells to present endogenous proteins to BW/G9 
hybrid cells was not tested, it has previously been determined that Kb-COS 
cells process and present transiently expressed ovalbumin (OVA) to an 
OVA/Kb restricted T cell clone (Karttunen et al., 1992). This demonstrates 
that cDNA plasmids are expressed and presented to T cells by COS-7 cells, and 
that COS-7 cells can function as efficient APCs for MHC class I-restricted NOD 
mouse T cells (diagrammed in Figure 3). 

Figure 6. COS-7 ceils transfected with MHC class I molecule H-2Kd, express Kd 
on their surface, as shown by staining with anti-Kd antibody HB519 (-), as 
compared to untransfected COS cells stained with anti-Kd (.). 
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2. Microscopic detection of lacZ -inducible T-cell hybrids in the 
presence of NOD mouse islets and the chromogenic substrate X-gal. 
The analysis of Kd-COS cells transfected with islet cDNA was 
performed using the /acZ-expressing T cell hybrids. Indicator T cells were 
visualized by staining with the chromogenic substrate, 5-bromo-4-chloro-3- 
indolyl-(3-D-galactopyranoside (X-gal). X-gal is cleaved by (3-galactosidase to 
yield 5,5'-dibromo-4,4'-dichloroindigo, which stains the lacZ -expressing T 
cells dark blue. It has previously been demonstrated by Karttunen et al (1992) 
that X-gal staining, used as a semi-quantitative or qualitative assay, is very 
sensitive for detecting activated, /acZ-expressing T cells, and therefore their 
corresponding ligand-expressing APCs. In those studies, ligand expressing Kb- 
COS cells were detected at a frequency of 1:103, when assayed in triplicates 
(Karttunen et al., 1992). 
The photomicrograph of X-gal-stained control samples, shown in 
figure 7, illustrate how activated focZ-expressing BW/G9 T cell hybrids are 
visualized as darkly staining blue cells, and are easily distinguishable from 
background, yellow APCs and non-activated T cell hybrids. Figure 7 
illustrates that BW/G9 T cell hybrids are islet specific; they turn blue in the 
presence of NOD mouse islets, which serve as a positive control for the 
LacZ/COS cell assay. As a negative control, BW/G9 cells are co-cultured with 
ovalbumin-expressing Kd-COS cells transfected with the OVA (P022) gene, 
and rarely turn blue (Table 2). The negative control illustrates that BW/G9 
cells do turn blue in the absence of the antigen, and this represents 
background lacZ activity that is significantly less than that seen with clones 
cultured in the presence of antigenic islets. 
It was observed that with time BW/G9 T cell hybrids gradually lost 
their ability to turn blue in the presence of islets. Hybrid T cells tend to 
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Figure 7. LacZ-inducible T cell hybrids turn blue in the presence of islets and 
the chromogenic substrate X-gal. Arrows indicate activated (blue) cells 
surrounding a NOD mouse islet. 
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proliferate extremely rapidly, and after 4 or 5 weeks in culture have passed 
through many cycles of cell division. It is unclear why the /tfcZ-expression of 
T cell hybrids became less inducible with time, though it may be related to the 
observation that T cell hybrids are inherently unstable. They tend to lose 
their TCRs, which would result in decreased reactivity to their ligands after 
several generations in vitro. Thus, T cell hybrids were discarded after about a 
month of culture, and fresh batches of frozen T cell hybrids were thawed and 
used in future assays. In addition, the background lacZ activity seen in the 
negative control assays was highest with newer T cell hybrids. The frequency 
of background X-gal stained T cells gradually decreased with time, thus 
paralleling the decrease in T cell activity seen in the positive controls. 
3. A pool of islet cDNA induces lacZ -expression in BW/G9 T cell 
hybrids. 
Using the lacZ/COS cell assay all 60 pools each containing about 5 x 105 
unique cDNA were screened. One pool of the islet cDNA library, when 
transfected into Kd-COS cells, appeared to induce increased lacZ activity in the 
islet antigen-specific T cell hybrids; about 20 blue cells per well, versus 2-3 blue 
cells per negative control well (Table 2). The antigenicity of the cDNA pool 
was suggested by the fact that there were increased numbers of blue, X-gal 
stained cells as compared to the negative control. However, although all of 
the T cells turned blue with equal intensity, the number of /acZ-expressing T 
cells in this pool did not approach that seen in the positive control. When 
this pool was subdivided into ten, smaller pools each containing 5 x 104 
transformants, and re-screened, similar numbers of activated T cells (about 5- 
10 fold more than the negative control) (Table 2) were again visualized. 
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Table 2. Representative numbers of lacZ expressing (blue) indicator T cells 
per well of potentially positive cDNA pools, and corresponding numbers in 
control (P022 expressing) wells. Counts are either numbers of clustered blue 
cells or the average number of blue cells/well in 5 wells. 
cDNA pool # # blue cells/well # blue cells/control well 
6 10 (cluster) 1-2 
14 6 (cluster) 1-3 
24 12 (cluster) 2-3 
24 (s.d.)a 40 3-4 
24 (s.d.) 36 3-4 
fls.d.; subdivided 
Thus, we continued this process of limited dilution, each time subdividing 
the pool which had yielded the most numbers of activated BW/G9 cells. 
4. Establishing the antigenicity of candidate cDNAs 
When a pool size of about 2 x 102 colonies was reached, individual 
cDNAs were transfected into wells of Kd-COS cells, and screened. Several 
such candidate cDNAs were associated with a 10-fold increase in lacZ activity 
above background, and were selected as candidate antigenic cDNAs, 
sequenced, and compared to known gene and amino acid sequences using the 
NCBI database and Swiss protein database, respectively. Three of these 
cDNAs were identified as the mRNAs coding for amylase, pre-proglucagon, 
and pre-proinsulin. However, when the corresponding peptides of known 
Kd motifs within these genes were tested for their antigenicity on Kd-COS 
cells and NOD spleen cells using proliferation assays with G9 clones, as well 
as lacZ assays with BW/G9 hybrids, no T cell activation was detected. 
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Furthermore, they candidate genes were re-tested by transfecting the cDNA 
into Kd-COS cells and again no significant (3-gal activity was detected in co¬ 
cultured T cell hybrids. Thus the G9 clones do not appear to be recognizing 
known Kd motifs within these proteins. However, it may be that 
unconventional Kd binding peptides exist within proteins such as pre¬ 
proinsulin, and these can perhaps be determined using a peptide scan 
technique. 
Other known (3-cell autoantigens were previously tested, in the form of 
peptides, for their antigenicity to the G9 T cell clones, using IL-2 proliferation 
assays and cytotoxic 51Cr-release assays. GAD65 and GAD67 were tested and 
not found to induce T cell activation. The antigenicity of insulin, proinsulin, 
and preproinsulin were additionally tested using these assays, as well as by 
directly adding peptides to the supernanent of Kd-COS cells co-cultured with 
BW/G9 T cell hybrids, and applying the lacZ assay. The peptides did not 
activate the T cell clones or hybrids, and thus do not appear to be the ligands 
recognized by these CD8 T cell clones. 
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Discussion 
1. Islet cell cDNA library 
Expression cloning of antigenic peptides, as an alternative to 
biochemical purification, is not dependent upon the total amount of 
obtainable protein, but requires the extraction of relatively large amounts of 
highly purified mRNA from the appropriate tissue, for the cDNA library 
construction. Thus, the availability of high quality starting material is critical 
for successful expression cloning strategies. The construction of this islet 
cDNA library used mRNA purified from the islets of 200 non-diabetic male 
NOD mice. The library is an unamplified library prepared from stringently 
size-selected cDNA (Edge Biosystems, Maryland). Although this cDNA 
library has been skillfully constructed from excellent starting materials, it can 
be that target antigens are resistant to cloning, as when they are too large (ie. > 
5 kb in size), or too small. The cut-off size of the islet cell cDNA library used 
in this study is 700 base pairs. Thus the cDNAs corresponding to very small 
proteins could be excluded from this library. 
2. MHC class I expressing COS cells and the lacZ expression cloning 
strategy. 
In this thesis we are applying a newly described expression cloning 
strategy in an effort to identify the antigen recognized by the diabetogenic CD8 
T cell clone. Here we show that COS-7 cells can stably express the NOD 
mouse Kd MHC class I allele at high levels (figure #). Our prediction that 
COS cells could function as APCs for NOD mouse Kd-restricted T cells was 
based on previous findings that the mouse Kb Class I molecule can interact 
appropriately with the simian antigen processing machinery existing in COS 
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cells (Karttunen et al, 1992). It was determined that OVA expressing Kb-COS 
cells activated a murine OVA/Kb-specific T cell, and that the peptide 
generated by the K^-COS cell was identical to the peptide generated by OVA 
expressing mouse cells. Furthermore, studies of antigen-MHC ligands have 
not revealed any instances of species specific antigen processing and peptide 
formation, suggesting that the antigen processing machinery is highly 
conserved amongst mammals (Falk et al., 1991; Karttunen et al., 1992). 
Therefore, it seems likely that we are using an expression cloning system 
which generates peptide-Kd ligands on transfected Kd-COS cells that would be 
identical to the peptides generated in similarly transfected Kd expressing 
mouse cells. Here we are assuming that the presence of the appropriately 
restricted MHC molecule is sufficient for the appropriate generation of 
peptide-Kd ligands. 
Despite the compatibility seen between the murine Kd MHC class I 
molecule and the COS cell's simian antigen processing machinery, it is 
important to consider the possibility that certain peptides may be resistant to 
processing and presentation of the Kd Class I pathway by COS cells. In order 
to demonstrate that Kd class I molecules process and present transfected 
cDNA appropriately in COS cells, we will determine whether Kd-restricted 
CD8 T cells, specific for the listeria P60 protein, are activated when co-cultured 
with Kd-COS cells transiently transfected with the P60 gene (provided by E. 
Pamer, Yale University School of Medicine). This model does not however 
directly test the ability of the G9 T cell clone to bind and become activated by 
peptide-Kd ligands on COS cells, and we would need to assume that our 
clone's TCR functions identically to that of the P60-Kd specific clone. 
This P60-Kd model will not only determine if the mouse Kd Class I 
molecule interacts appropriately with the COS cell's antigen processing 
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machinery, but will also serve as a marker for successful transfections during 
the islet library screening process. The timely screening of 107 clones in the 
islet library required the semi-synchronous transfection of many cDNA pools. 
As a result COS cells were not consistently exposed to the Superfect reagent 
for the same length of time. Over-exposure to the Superfect reagent is 
damaging to cells. Therefore some pools may have been transfected for sub- 
optimal amounts of time, whereas others may have been transfected for too 
long, and therefore damaged. This variation in transfection efficiency could 
be monitored using the P60-Kd-specific T cells and P60 expressing Kd-COS, 
and the most efficient transfection time-span could be determined. 
3.LacZ -inducible BW/G9 T cell hybrids 
A. Increasing the sensitivity of the lacZ assay 
As an alternative to conventional T cell activation assays, the 
particular strategy used here takes advantage of an NFAT-lacZ reporter which 
has been incorporated into the BW5147 fusion partner. BW cells were fused 
to the diabetogenic CD8 T cell clone, G9, to generate lacZ-inducible BW/G9 T 
cell hybrids. Here we demonstrate that when activated by NOD mouse islets, 
BW /G9 hybrids express the lacZ gene, and turn dark blue in the presence X- 
gal (figure 7). As such, these hybrids have been used as a single T cell 
activation assay to probe for ligand expression on APCs. Previously, this assay 
has been shown in the model system using ovalbumin, to be sufficiently 
sensitive to allow the detection of OVA cDNA at a frequency of 1:103 - 104 
(Karttunen et al., 1992). Here we used lacZ-indicator BW/G9 to probe for 
antigenic cDNAs in large pool sizes of 5 x 105 cDNAs. Assuming that the 
BW/G9 hybrids are as sensitive as the OVA specific B3Z indicator cells, and 
that the autoantigenic cDNA is abundant in the library, then our primary 
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screen should detect the peptide-ligand within these pools. However, at this 
point we have screened the entire library divided into 60 such pools, and no 
potentially positive signal has led to the identification of an antigenic cDNA. 
This represents an inherent difficulty that can be encountered with 
expression cloning strategies, where the target mRNA is rare and poorly 
represented in the islet cell library, and thus remains undetected by indicator 
T cells during the primary screening of very large pools of cDNA. 
This difficulty can be addressed in two ways. First, the library screening 
can be carried out using smaller pools of cDNA, and we have begun the 
process of subdividing large pools into ten-fold smaller (104 cDNA) pools of 
cDNA. This will increase the proportion of candidate cDNAs within each 
pool, bringing their frequency into a range that the T cell hybrids are able to 
detect. However, this also creates a ten-fold increase in the number of pools 
to be screened, significantly increasing the time and effort involved in 
screening the library. The second approach is to increase the sensitivity of the 
BW/G9 hybrids. Since we do not know the antigen-specificity of the T cell 
hybrids (that is what we are determining), we cannot directly measure their 
sensitivity. Yet, it is possible to evaluate the BW/G9 hybrids' general 
reactivity through their co-culture with target tissue (ie. pancreatic islets), 
assuming that the T cell ligand is expressed at consistent densities on islet 
cells. It can be expected that the more sensitive the hybrids are the more will 
turn blue in the presence of islets. Recently, findings indicate that the 
efficiency of the NFAT-/flcZ reporter construct varies depending on where it 
is incorporated into the indicator cell's genome (J. Karttunen, personal 
communication). The BW hybrid partner used here already contained the 
reporter construct in the DNA at the time it was fused to the G9 clone. Thus, 
the most highly islet-reactive BW/G9 hybrids were selected for, but with the 
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lacZ reporter fixed in one position. Thus, an approach to increasing the 
sensitivity of the indicator T cell hybrids is to first fuse the G9 clone to the BW 
fusion partner, without the lacZ reporter, and select for the BW/G9 hybrids 
most highly activated by islets. Following this, the NFAT-/acZ reporter 
construct can be transfected into these hybrids, where once again the most 
highly /acZ-expressing cells are selected for. 
B. Pursuing a potentially positive signal by limiting dilution 
By far the biggest undertaking in the screening of a library is the task of 
identifying a primary pool of cDNA which contains the sought after antigen. 
This is because many factors, such as the abundance of autoantigen cDNA, 
and the sensitivity of indicator T cells, which are contingent on the feasibility 
of the expression cloning strategy, are unknown. However, once a positive 
pool is identified, the process of limiting dilution should facilitate the further 
identification of positive, sub-divided pools. This is because the candidate 
cDNAs are more highly represented in successive subdivisions, and should 
yield increased levels of lacZ activity in indicator T cells. In fact, it has been 
suggested that soon after the enrichment of a pool containing antigenic 
cDNAs, a positive signal could exponentially increase from a rare cluster of 
blue cells to the generation of many ZacZ-positive wells, similar to those seen 
with islet-activated hybrids (Karttunen et al., 1992). However, this is not clear 
with our BW/G9 hybrids. We did not observe this phenomenon when a 
potentially positive pool, which had yielded a small cluster of blue cells, was 
pursued by limiting dilution. The lacZ activities remained only slightly 
greater (about 10 fold more blue cells) than background levels on subsequent 
sub-divisions. It may be that this was a false positive signal. On the other 
hand, attaining large increases in a signal may be possible only when the 
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antigen is expressed at levels found in vivo. This level may be very high, and 
may be reached only using small pool sizes at the end of the dilution process. 
For these reasons, we pursued this potentially positive signal until individual 
cDNAs were isolated and tested for their antigenicity. 
Pursuing a potentially positive signal in the absence of further feedback 
information (ie. confirming that the signal is real) risks investing a 
tremendous amount of time and effort into the isolation of candidate cDNAs 
which are not the true autoantigens recognized by the indicator T cell. 
Therefore, it would be extremely useful to have a second equally sensitive 
assay, which can be used concomitantly with the lacZ assay, to substantiate a 
potential positive signal. For instance, the G9 T cell clone itself is very 
sensitive, and proliferates efficiently in the presence of islets. The clones 
could perhaps confirm a positive lacZ assay by using proliferation and/or 
cytotoxic assays with the pool in question. It must be noted, however, that as 
with T cell hybrids, these clones can proliferate non-specifically, generating 
background signals which are difficult to distinguish from weakly positive 
signals. Alternatively, Boon and colleagues have successfully identified the 
antigens of several tumor-specific CD8 T cells (Boon et al., 1989). They have 
done so using an expression cloning strategy where the library was screened 
in stably transfected APCs and tested for their ability to stimulate tumor 
necrosis factor (TNF) release by cytotoxic CD8 T cells (Traversari et al., 1992; 
van der Bruggen et al., 1991). Though stable transfections, as compared to 
transient transfections, take longer to establish, such an approach may prove 
useful as a second assay to confirm positive signals generated by the lacZ 
assay. 
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C. Stability of lacZ-inducible BW/G9 hybrids 
It was observed that after several weeks in culture BW/G9 T cell 
hybrids would gradually lose their islet-cell reactivity. The BW fusion 
partner of these hybrids is an immortalized cell which allows the hybridomas 
to multiply indefinitely. As a result, T cell hybrids tend to proliferate 
extremely rapidly, and undergo many cell divisions over short periods of 
time. As with many tumor cell lines, T cell hybrids are inherently unstable 
cells, and over time tend to lose essential surface molecules including their 
TCRs, CD8, and CD3 molecules. During the screening, it was also observed 
that as with the positive controls, hybrids had less background LacZ activity 
over time. Having decreased non-specific background fortunately 
compensated for the fact that the T cell hybrids also became less sensitive with 
time. Furthermore, as a means of maintaining islet-reactive hybrids in 
culture, frozen stocks of new hybrids were thawed to replace old hybrids every 
fourth week. Nonetheless, the gradual loss of T cell reactivity from one 
weekly set of transfections to the next does add some degree of variation to 
the sensitivity of our T cell probe. Since the feasibility of expression cloning 
requires that the lacZ assay be sensitive enough to detect antigen-expressing 
APCs at low frequencies, it would be advantageous to use indicator cells that 
did not tend to lose their reactivity to antigen. One option is to incorporate 
the lacZ reporter construct directly into the T cell clones, which proliferate 
indefinitely when cultured with islets, and have no propensity to lose their 
sensitivity to antigen over time. These highly responsive clones could then 
be used to screen for their autoantigen using a lacZ assay. The successful 
development of such indicator T cells would however be limited by the fact 
that T cell clones are notoriously difficult to permanently transfect (S. Wong, 
personal communication). 
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4. Nature of the autoantigenic target of CD8 T cells, cloned from 
young NOD mice. 
A. Confirmation of peptide antigenicity 
Following the isolation of candidate cDNAs by limiting dilution, they 
will be sequenced in order to identify the nature of the antigen. These 
sequences can then be used to isolate and characterize the genomic DNA 
sequences of these genes. As described in the results section, follow-up 
experiments with these candidate antigens can then done in order to establish 
their antigenicity. Identifying the cDNA and thus the amino acid sequence of 
candidate antigens will allow the construction of the minimal peptide 
determinants within the autoantigen sequence, based on the motifs specific 
for the Kd reported by Ramensee and colleagues (Falk et al., 1991). This will 
allow the identification of the peptide antigen in a functional assay and 
reduces the amount of screening of a possibly much larger protein sequence. 
Flowever, if the computer-directed synthesis of Kd motifs does not identify 
antigenic peptides within candidate genes, we will consider examining these 
sequences using peptide scans. Peptide scan technology is available in our lab, 
and entails synthesizing and screening peptides, about 8-10 amino acids in 
length, within a given protein. This approach may well turn up an 
unconventional Kd binding peptide perhaps in the pre-proinsulin sequence. 
The identification of the CD8 T cell autoantigen will also provide a different, 
and presumably much more efficient, method of growing the cloned T cell 
lines. This could potentially simplify the isolation and propagation of T cell 
clones without the continuous need for islets as a source of antigen. 

56 
B. Diversification of the T cell autoimmune response 
It will be important to determine whether or not all of the cloned T cell 
lines derived from young NOD islets (Wong et al., 1996) are responsive to the 
same autoantigen. This question can also be applied to the lab's previously 
isolated T cell clones (Reich et al., 1989). These were isolated from mice at a 
much more advanced stage of the disease process. This would support the 
hypothesis that in diabetes, as with other experimental autoimmune diseases, 
the initial disease stages involves a T cell response to a very specific antigen 
on (3 cells. It has been established that both autoreactive T cells and T-cell- 
dependent autoantibodies that characterize organ-specific autoimmune 
diseases recognize several distinct molecules, most of which are restricted to 
the target cells. This suggests that intermolecular epitope spreading takes 
place during autoimmune responses. In addition, the recent observation that 
a very limited number of V(3-genes and VDJ-sequences are possibly used by T 
cells isolated from single islets, suggests that pathogenic T cell infiltrates 
originate from a limited number of T cell clones (Sarukhan et al., 1995). 
Thus, a diversity of CD8 T cells, derived from older mice, would be consistent 
with the diversification of the T cell response as diabetes progresses. 
C. Islet-specificity of the CD8 T cell autoantigen 
Once a candidate cDNA is identified as being antigenic, further 
investigation into the islet-specificity of this antigen will be carried out. Since 
the peptide antigen is presented in the context of MHC class I, a molecule 
which is expressed ubiquitously in other tissues, it will be interesting to 
determine whether the identified autoantigen is expressed in and presented 
by other tissues. Furthermore, it will be determined whether the autoantigen 
is presented on the islets of other non-NOD mice which express the same or 
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different MHC class I molecule. In principle this has been demonstrated 
where the diabetogenicity of the CD8 clones is preserved when transferred to 
H-2Kd expressing CB17.scid mice, but not B6.scid, which express H-2Kb (Wong 
et al., 1996). 
Interestingly, when several candidate cDNAs were sequenced and 
identified, one was identified as the P cell specific molecule, preproinsulin, 
whereas two others were identified as preproglucon, synthesized by islet a 
cells, and a-amylase, produced by the exocrine pancreas. Although none of 
these proteins appear to be the antigen recognized by these cloned CD8 T cells, 
their diversity raises the interesting question of whether the CD8 T cells 
recognize an antigen expressed only on the islet P cells, or if they can be 
triggered by antigen-expressing islet a cells, or even the exocrine pancreas, 
before going on to destroy P cells. It is possible that this would take place if 
the inciting cell, expressing B7 co-stimulatory molecules, activated reactive T 
cells and led to the expression of FasL on the T cell (Alderson et al., 1995; 
Russell et al., 1993). When these FasL-expressing activated T cells encounter P 
cells which bear the Fas receptor on its surface, P cells could undergo 
apoptosis (Chervonsky et al., 1997). On the other hand, it has recently been 
demonstrated that class I-restricted CD8 T cells can be stimulated by human 
dendritic cells, which efficiently present antigen acquired from self-tissue 
(Albert et al., 1998). This suggests that cytotoxic T cells are not restricted to 
recognizing antigens that are solely synthesized in the cytoplasm of their 
target cells. 
Nonetheless, there exists strong evidence that the antigenic targets of 
cytotoxic T cells are expressed on the islet P cells themselves. All of the 
autoantigens identified to date in IDDM are expressed on islet P cells. In fact 
insulin and proinsulin are expressed only by P cells. Furthermore, it has been 
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shown that the transfer of diabetogenic T cells into (3-cell-depleted NOD mice 
(whose (3 cells have been selectively destroyed) does not allow the survival of 
such cells, as demonstrated by their inability to cause diabetes in a secondary 
transfer into prediabetic NOD mice bearing functional P cells (Larger et al., 
1995). This suggests that islet P cells bear the target antigens of these 
diabetogenic T cells and drive the autoimmune response. Finally, type 1 
diabetic patients show decreasing titers of P-cell specific autoantibodies which 
eventually disappear following the clinical onset of their disease, when all P 
cells are destroyed (Irvine et al., 1977). Similarly, these autoantibodies rapidly 
reappear following islet or pancreas transplantation (Sutherland et al., 1984). 
5. Antigen-specific immunotherapy 
A very important goal once, and if, an autoantigen is elucidated, is to 
explore the potential use of the antigen as a treatment modality for disease 
prevention. Autoantigen-based immunotherapy has previously been 
attempted by targeting the autoreactive T cells for immune intervention. 
One way to block their pathogenic activity is to induce tolerance in the 
autoreactive T cells by using autoantigen-derived peptides. This selectively 
eliminates the unwanted T cells. Here, it will be determined if the 
autoantigenic peptide can be manipulated such that it binds to T cell but does 
not induce a response, thus effectively antagonizing the T cell response. 
These antagonist peptides could be used in the NOD mouse in vivo to 
prevent disease. The autoantigenic peptide will be mutated to generate 
variant peptides, which can then be characterized in vitro using agonist 
peptides and the cloned cells. T cell hybrids will also be used to test for 
antagonizing effects of these peptides. Once antagonist peptides are identified 
in vitro, they will then be injected into mice and tested for their in vivo 
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ability to inhibit diabetes. Another antigen-specific approach to inhibit the 
activity of the diabetogenic T cells is through oral and nasal administration of 
antigen or antigenic peptides. Such immunotherapy was carried out using 
GAD and insulin, and resulted in the down-regulation of self-reactive T cells, 
and in the case of insulin, the production of protective gamma-delta (y5) T 
cells (Harrison et al., 1996; Tian et al., 1996; Zhang et al., 1991). Thus, oral 
tolerance may prove to be another method by which the CD8 T cell 
autoantigen can be used to treat and prevent disease. 
Previous studies have shown that the treatment of young mice with 
the {3-cell antigen GAD, can tolerize GAD-specific T cells and in turn prevent 
diabetes in the NOD mouse (Kaufman et al., 1993; Tisch et al., 1993). This 
protection seems to result from the induction of a protective Th2-like 
response (Zechel et al., 1997). Intrathymic administration of GAD, as a means 
of inducing a central tolerance (by deletion), has been less conclusive, and 
some authors have even found peptide administration to exacerbate the 
diabetic process rather than delay or suppress it (Cetkovic-Cvrlje et al., 1997). 
More recent studies have demonstrated tolerance induction to insulin 
(French et al., 1997; Muir et al., 1995; Zhang et al., 1991), and down-regulation 
of T cell reactivities to HSP60 protects NOD mice from diabetes (Birk et al., 
1996; Elias and Cohen, 1994). In the case of multiple sclerosis (MS), treatment 
with immunodominant peptides of the myelin basic protein (MBP) can 
prevent and treat the CD4 T cell-mediated murine model of experimental 
autoimmune encephalomyelitis (Smilek et al., 1991; Wraith et al., 1989). 
Thus, it appears that peptide-specific immunotherapy, when applied to highly 
defined models of autoimmunity, can be effective. 
In diseases such as IDDM, or MS, in which the target autoantigen(s) is 
not known and a number of autoantigens appear to be involved in the 
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disease process, it is less clear how such a peptide-specific approach could be 
feasible. At this time there is no consensus as to which antigens in IDDM are 
most effective in this process. However, studies do suggest that this form of 
immunotherapy may be successful in a clinical setting, where success hinges 
on whether the therapy can be used to treat an ongoing autoimmune 
response or whether it can be useful only in disease prevention (Tisch and 
McDevitt, 1994). Furthermore, there are many questions that remain 
unanswered. How many (3-cell autoantigens have not been identified, and do 
primary or triggering antigens exist in NOD mice? How are NOD mouse 
autoantigens similar to or different from human (3-cell antigens? In the past, 
most assays have focused on the antigens recognized by CD4 T cells. It is now 
becoming apparent that CD8 T cells play a critical role as initiators of insulitis. 
Thus, it is likely that by elucidating the autoantigens recognized by CD8 T 
cells, we will be able to address many of these unanswered questions. 
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Conclusion 
In this thesis we describe the application of the lacZ assay as a means of 
identifying the target antigen of a CD8 T cell clone, isolated from young NOD 
mice, which transfers rapid-onset diabetes in the absence of CD4 T cells. 
Defining the ligands of T cells involved in IDDM is an extremely important 
component of understanding the immunological mechanisms underlying 
diabetogenesis and autoimmunity in general. CD8 T cells appear to be critical 
initiators of diabetes, and it may well be that the antigenic targets of CD8 T 
cells play a role in disease induction. However, the antigenic targets of CD8 T 
cell have not been identified in type 1 diabetes. Their identification may 
provide insight into the existence and nature of a primordial autoantigen in 
the pathogenesis of IDDM. Identifying T cell autoantigens has been a difficult 
task. Here we make use of an expression cloning strategy which takes 
advantage of a highly sensitive single-cell T cell assay. We aim to manipulate 
the IcicZ assay in an effort to further increase the sensitivity of the indicator T 
cells, and continue to screen the islet cDNA library in smaller pools. This will 
help to enable our endeavor to identify the autoantigen of the diabetogenic 
CD8 T cell clone, and subsequently explore its potential as a treatment 
modality for disease prevention. 
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